Ranjit K. Thirumaran

Evaluating Patient Adherence and Persistence to Tyrosine-Kinase Inhibitors for Metastatic Renal Cell Carcinoma: A Retrospective Analysis of Real-World Data

Zhaohui Arter, David J. Benjamin, Yen Cao, Jorge G. Farías et autres

Background: Combination therapy using an immune checkpoint inhibitor (ICI) and a tyrosine kinase inhibitor (TKI) is the standard first-line treatment for metastatic renal cell carcinoma (RCC). Oral TKIs enhance patient autonomy but require strict adherence and persistence. Methods: We analyzed adults with …

us (code pays fourni par la source)

Evaluating patient adherence and persistence to first-line tyrosine-kinase inhibitors for metastatic renal cell carcinoma.

Zhaohui Arter, David J. Benjamin, Yen Cao, Michael Forsyth et autres

e18856 Background: Tyrosine kinase inhibitors (TKIs) have been approved in treating advanced renal cell carcinoma (RCC) since 2005. More recently, combination therapy with an immune checkpoint inhibitor (ICI) and a kinase inhibitor (TKI) is considered standard of care in the first-line setting …

us (code pays fourni par la source)

Exploration of CYP450 and drug transporter genotypes and correlations with nevirapine exposure in Malawians

Hsiao-Chuan Tien, Jean Tauzie, Howard L. McLeod, Jatinder K. Lamba et autres

Genetic polymorphisms have the potential to influence drug metabolism and vary among ethnic groups. This study evaluated the correlation of genetic polymorphisms with nevirapine pharmacokinetics exposure in Malawians.

Clinical impact of pharmacogenetic profiling with a clinical decision support tool in polypharmacy home health patients: A prospective pilot randomized controlled trial

Lindsay S. Elliott, John C. Henderson, Moni B. Neradilek, Nicolas Moyer et autres

BACKGROUND: In polypharmacy patients under home health management, pharmacogenetic testing coupled with guidance from a clinical decision support tool (CDST) on reducing drug, gene, and cumulative interaction risk may provide valuable insights in prescription drug treatment, reducing re-hospitalization and emergency department (ED) …

us (code pays fourni par la source)

Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting

Lisa V. Kalman, José A. G. Agúndez, Malin Lindqvist Appell, Gillian C. Bell et autres

Cytochrome P–450 gene and drug interaction analysis in patients referred for pharmacogenetic testing

Brian Hocum, John R. White, Jarrod W. Heck, Ranjit K. Thirumaran et autres

PURPOSE: The results of a study of variant cytochrome P-450 (CYP) alleles and associated risks of drug-drug interactions (DDIs) and altered drug metabolism are reported. METHODS: The records of a pharmacogenetic testing laboratory were retrospectively analyzed to identify patients tested for polymorphisms …

us (code pays fourni par la source)

CYP450 Genotyping and Cumulative Drug–Gene Interactions: An Update for Precision Medicine

Ranjit K. Thirumaran, Jarrod W. Heck, Brian Hocum

us (code pays fourni par la source)

In Vivo Imaging of Human MDR1 Transcription in the Brain and Spine of MDR1-Luciferase Reporter Mice

Kazuto Yasuda, Cynthia Cline, Yvonne S. Lin, Rachel Scheib et autres

ca, us (code pays fourni par la source)

Genetic variation in aldo‐keto reductase 1D1 (AKR1D1) affects expression and activity of multiple cytochrome P450s (LB595)

Amarjit S. Chaudhry, Ranjit K. Thirumaran, Kazuto Yasuda, Xia Yang et autres

Human liver gene regulatory network analysis identified a cytochrome P450 subnetwork with AKR1D1 as its key regulatory driver. This study assessed the biologic importance of AKR1D1 [key enzyme in synthesis of bile acids, ligand activators of FXR, PXR and CAR, known P450 …

us, se (code pays fourni par la source)

Genetic variation in aldo‐keto reductase 1D1 (AKR1D1) affects expression and activity of multiple cytochrome P450s (292.1)

Amarjit S. Chaudhry, Ranjit K. Thirumaran, Kazuto Yasuda, Xia Yang et autres

Human liver gene regulatory network analysis identified a cytochrome P450 subnetwork with AKR1D1 as its key regulatory driver. This study assessed the biologic importance of AKR1D1 [key enzyme in synthesis of bile acids, ligand activators of FXR, PXR and CAR, known P450 …

us, se (code pays fourni par la source)

Genetic Variation in Aldo-Keto Reductase 1D1 (AKR1D1) Affects the Expression and Activity of Multiple Cytochrome P450s

Amarjit S. Chaudhry, Ranjit K. Thirumaran, Kazuto Yasuda, Xia Yang et autres

us, se (code pays fourni par la source)

Drug Transporters on Arachnoid Barrier Cells Contribute to the Blood–Cerebrospinal Fluid Barrier

Kazuto Yasuda, Cynthia Cline, Peter Vogel, Mihaela Onciu et autres

us, jp (code pays fourni par la source)